Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01643603
Recruitment Status : Active, not recruiting
First Posted : July 18, 2012
Last Update Posted : January 4, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Abhinav Deol, Barbara Ann Karmanos Cancer Institute

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : January 31, 2019
Estimated Study Completion Date : January 31, 2019
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 April 10, 2019
May 2, 2019